May, 2009

U.S.A.
News / Therapeutic Area News
Astellas Receives FDA Approval For Use of Prograf® (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Deerfield, IL (May 28, 2009) – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf® (tacrolimus) in conjunction with mycophenolate...
Read More
U.S.A.
News / Therapeutic Area News
Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y., May 14, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced detailed results from the Phase III SATURN study of Tarceva(R) (erlotinib) as a single agent,...
Read More

Mar, 2009

U.S.A.
News / Therapeutic Area News
Astellas Launches Vaprisol® (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
DEERFIELD, Illinois, April 1, 2009 — Astellas Pharma US, Inc. today announced the commercial availability of Vaprisol® (conivaptan hydrochloride injection) Premixed in 5% Dextrose, a new...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2009-- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Genentech, Inc., (NYSE: DNA) today announced that OSI submitted a...
Read More

Feb, 2009

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva
MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 10, 2009-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...
Read More